<- Go Home
Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is CM-101, a humanized monoclonal antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.
Market Cap
$30.7M
Volume
492.2K
Cash and Equivalents
$6.6M
EBITDA
-$15.3M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$2.55
52 Week Low
$0.42
Dividend
N/A
Price / Book Value
1.88
Price / Earnings
-1.67
Price / Tangible Book Value
1.88
Enterprise Value
$11.7M
Enterprise Value / EBITDA
-0.76
Operating Income
-$15.4M
Return on Equity
83.81%
Return on Assets
-43.37
Cash and Short Term Investments
$19.4M
Debt
$342.0K
Equity
$16.3M
Revenue
N/A
Unlevered FCF
N/A
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium